-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Radiotherapy (RT) is one of the main treatments for head, neck and/or skull-related tumors.
this method is currently common, there are serious complications.
, radioactive optic neuropathy (RION) is a serious late-oncward complication caused by radiation therapy (EBRT).
RION may occur on one or both sides and cause acute or irreversible vision impairment and vision loss.
because the detailed pathogenesis of RION is not yet known, an in-depth study of RION pathogenesis will help to develop effective interventions and improve the quality of life of radiotherapy patients.
study found that radiotherapy causes changes in mitochondrial dynamics by regulating mitochondrial division-related proteins Drp1 and Fis1, while producing too much reactive oxygen (ROS), which eventually leads to neuron damage and visual impairment.
In addition, the researchers found that an important mechanism in the rion process, Cdk5 (cell cycle protein-dependent kinase 5), was able to regulate mitochondrial dynamics defects associated with neuron damage by mediated phosphatization of Drp1's 616th bit of ser616.
the use of Cdk5 inhibitors roscovitine and Drp1 inhibitors mdivi-1 in pharmacology can inhibit mitochondrial division and the production of ROS associated with radioactive neuron damage.
, the above findings are of great clinical significance in preventing RION.
.
